TessArae, LLC and Kindstar Global have signed a collaboration agreement for the development of a pan-ethnic carrier screen for the Chinese population. The assay, which will be run in Kindstar's laboratories in China, employs TessArae's targeted sequencing development platform and proprietary bio-analysis software. The agreement solidifies a development partnership which allows Kindstar to leverage TessArae's design expertise to create and market its own Laboratory Developed Test (LDT) specific to the Chinese market.

TessArae's development platform combines a highly multiplexed amplification strategy with a standard Affymetrix microarray protocol. Results are delivered as genomic sequence, automatically generated and analyzed by TessArae's GeneCipher algorithms.